Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

SAN DIEGO, March 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.  Additionally, investors received Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering were $7.75 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by OncoSec, were approximately $7.2 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.  Roth Capital Partners, LLC served as financial advisors to the Company in the offering.

About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and ot
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 The Pittcon Organizing Committee is ... Food Safety Tech , an e-Journal and producer of ... for the second year for the co-location of Food Labs ... partnership provides that the registration fee to attend the two-day ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Md., Sept. 13 Total Site Solutions,(TSS), a ... who provides,comprehensive services for the planning, design and ... in the,pharmaceutical and biotech industry has awarded them ... Project. TSS originally performed technology consulting services ...
... Sept. 13 Southern Research,Institute today announced that ... as SR9025, to Virium Pharmaceuticals, Inc. To date, ... approval and are on,the market. Six others, including ... early clinical trials. (Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals 2Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... they,re planted may be good news for a garden. But ... a plant whose seeds sprouted at the first ,warm spell ... insurance policy against late frosts or unexpected dry spells, it ... Plants whose seeds put off sprouting until conditions are more ... of researchers working at the National Evolutionary Synthesis Center in ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2
... time in the developing mind, Daniel Casasanto of the ... and colleagues at the Aristotle University of Thessaloniki and ... along parallel paths for different distances or durations. The ... each race, reporting which animal went for a longer ...
... executed two license agreements with SuperPower, a wholly-owned ... the intellectual property on second generation (2G) high ... the Sponsored Research Agreement (SRA) previously executed between ... led by Venkat Selvamanickam, M.D. Anderson chair professor ...
... March 31, 2010 Mariam El-Ashmawy, a student ... Training Program, has been awarded a 2010 Gilliam Fellowship ... (HHMI). Ms. El-Ashmawy, a Lewisville native, is one ... selected this year from institutions across the country. Each ...
Cached Biology News:Children use space to think about time 2SuperPower and UH sign high temperature superconducting wire license agreements 2UT Southwestern student receives fellowship from Howard Hughes Medical Institute 2